Company Overview and News
Today, few investors have a plan to invest in recession-proof stocks. With high economic growth and a tight job market, optimism remains high. However, downturns always follow such periods.
TMUS COST JBLU NFLX SAVE STZ BIG CGC DLTR TDOC TAP TWMJF S AMZN T WEED DG VZ DIS LUV
SAP SE (SAP - Free Report) reported second-quarter 2018 non-IFRS earnings of €0.98 ($1.17) per share, up 4.3% on a year-over-year basis. However, the bottom line fell short of the Zacks Consensus Estimate of $1.18 per share. On IFRS basis, earnings of €0.60 (71 cents) per share increased 7.1% on a year-over-year basis. Total revenues, on non-IFRS basis, were €6.01 billion ($7.15 billion), up 4% year over year (up 10% at constant currency), better than the Zacks Consensus Estimate of $7.
SAP VRNT SAPGF SAVE DTEGF ADBE DTEGY
In the past week, Delta Air Lines, Inc. (DAL - Free Report) kick-started the second-quarter earnings season for the airline space. This Atlanta, GA-based carrier reported better-than-expected revenues and earnings per share. However, Delta trimmed its projection for current-year earnings per share citing high fuel costs.
AAL HA JBLU SAVE UAL DAL
From the age of 25–40, my range of emotions could generously be described as “narrow.” I loved nobody, and the only real emotions I felt were satisfaction or disappointment from my ambition as I howled in the money storm. My approach to life could best be summarized as “I want more, f***ing more.” Problem is, “more” started getting harder to define. During that 15-year period, I laughed out loud a lot less than before and didn’t cry once.
FB TM AAL TWX JBLU NFLX SAVE GOOG UAL TWC AMZN T GOOGL VZ DAL DIS
From the age of 25–40, my range of emotions could generously be described as “narrow.” I loved nobody, and the only real emotions I felt were satisfaction or disappointment from my ambition as I howled in the money storm. My approach to life could best be summarized as “I want more, fucking more.” Problem is, “more” started getting harder to define. During that 15-year period, I laughed out loud a lot less than before and didn’t cry once.
TWX SAVE TWC
When evaluating stocks to buy, investors tend to look for positive factors that can lead to a competitive edge. Such an edge happens when companies move ahead of their peers in a sector or when they develop a product enhancement or build a market in an existing industry.
FOX JBLU SAVE AMD NFLX NVDA AMZN MU AAPL ALGT FOXA DIS LUV
Spirit Airlines, Inc. (SAVE - Free Report) was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $35.37 –$39.61 in the past one-month time frame, witnessed a sharp increase yesterday.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AAL SAVE DAL
MIRAMAR, Fla., July 11, 2018 (GLOBE NEWSWIRE) -- Just when the winter chill will be ready to take hold, here come more options for a warm tropical escape with Spirit Airlines (NYSE:SAVE). Beginning November 8, 2018, Spirit will start daily nonstop service from Newark Liberty International Airport (EWR) to Las Américas International Airport (SDQ) in Santo Domingo, Dominican Republic*. On December 20, Spirit will grow again and begin nonstop seasonal service between Detroit Metro Airport (DTW) and Sangster International Airport (MJB) in Montego Bay, Jamaica* running three times weekly.
Even though we are right in the middle of the busy summer travel and vacation season, there are mounting reasons why the airlines need to be viewed with caution. The rise in oil pricing should precipitate a rise in jet fuel prices, which is, of course, a major cost component for the industry. Toss in some other headwinds, and it makes sense for investors to be careful.
DB JBLU SAVE ALK LUV
(Reuters) - Haitian leaders pleaded for calm on Saturday as violent protests over fuel price increases entered a second day and U.S. airlines canceled flights to the Caribbean nation.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET